南模生物股价涨5.71%，融通基金旗下1只基金位居十大流通股东，持有80万股浮盈赚取247.2万元

Group 1 - The core point of the article highlights the performance and financial metrics of Nanmo Biotechnology, which saw a stock price increase of 5.71% to 57.24 CNY per share, with a total market capitalization of 4.463 billion CNY [1] - Nanmo Biotechnology specializes in the research, production, and sales of genetically modified animal models, with its main revenue sources being standardized models (48.34%), model technical services (21.92%), model breeding (19.50%), customized models (9.34%), and other services (0.91%) [1] - The company is located in Shanghai and was established on September 20, 2000, with its listing date on December 28, 2021 [1] Group 2 - Among the top shareholders of Nanmo Biotechnology, the Rongtong Health Industry Flexible Allocation Mixed A/B fund (000727) reduced its holdings by 150,000 shares in the second quarter, now holding 800,000 shares, which represents 1.03% of the circulating shares [2] - The Rongtong Health Industry Flexible Allocation Mixed A/B fund has a current scale of 2.074 billion CNY and has achieved a year-to-date return of 20.36%, ranking 4289 out of 8244 in its category [2] - The fund has delivered a one-year return of 44.25%, ranking 3678 out of 8066, and a cumulative return of 190.8% since its inception on December 25, 2014 [2]